Moderna said Monday that its two-dose COVID-19 vaccine generates a weaker immune response against a worrisome strain of the disease that first emerged in South Africa, prompting the firm to plan a clinical trial in the United States of a “booster” shot that recipients would receive.
The Cambridge biotech said the South African variant caused a six-fold reduction in neutralizing antibodies generated by the vaccine cleared last month for emergency use by the Food and Drug Administration, based on a new Moderna study. While that’s a dramatic decrease, the company said those antibody levels are still enough to protect people against the South African strain.
Read the full story on BostonGlobe.com.
|
|
|
|
|
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
|
|
|
|
